{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:37:52Z","timestamp":1792060672608,"version":"4.4.0"},"reference-count":138,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.ejca.2006.01.025","type":"journal-article","created":{"date-parts":[[2006,3,31]],"date-time":"2006-03-31T12:14:54Z","timestamp":1143807294000},"page":"1014-1030","source":"Crossref","is-referenced-by-count":335,"title":["EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome"],"prefix":"10.1016","volume":"42","author":[{"given":"Franz","family":"Trautinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Knobler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rein","family":"Willemze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolph","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliane","family":"Laroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"D\u2019Incan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamari","family":"Ranki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Pimpinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Ortiz-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Estrach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Whittaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2006.01.025_bib1","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1056\/NEJMra032810","article-title":"The pathogenesis of mycosis fungoides","volume":"350","author":"Girardi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2006.01.025_bib2","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1200\/JCO.2000.18.10.2152","article-title":"Primary cutaneous B-cell lymphoma: review and current concepts","volume":"18","author":"Pandolfino","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.01.025_bib3","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1200\/JCO.2000.18.15.2908","article-title":"Primary cutaneous T-cell lymphoma: review and current concepts","volume":"18","author":"Siegel","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.01.025_bib4","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI200524826","article-title":"Immunopathogenesis and therapy of cutaneous T cell lymphoma","volume":"115","author":"Kim","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2006.01.025_bib5","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2005-03-1175","article-title":"Primary cutaneous large B-cell lymphomas. Clinicopathologic features, classification, and prognostic factors in a large series of patients","author":"Kodama","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.01.025_bib6","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.01.025_bib7","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood.V88.7.2385.bloodjournal8872385","article-title":"Mycosis fungoides and Sezary syndrome","volume":"88","author":"Diamandidou","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.01.025_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1067\/mjd.2002.118538","article-title":"Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas","volume":"46","author":"Vonderheid","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib9","first-page":"1372","article-title":"Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II","volume":"89","author":"Paulli","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2006.01.025_bib10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jama.1988.03410010050033","article-title":"Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology","volume":"260","author":"Weinstock","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2006.01.025_bib11","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.2105\/AJPH.89.8.1240","article-title":"Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality","volume":"89","author":"Weinstock","year":"1999","journal-title":"Am J Public Health"},{"key":"10.1016\/j.ejca.2006.01.025_bib12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1046\/j.1523-1747.2000.00011.x","article-title":"Increased risk of secondary cancers in patients with primary cutaneous T cell lymphoma","volume":"115","author":"V\u00e4kev\u00e4","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib13","first-page":"276","article-title":"Mycosis fungoides and the Sezary syndrome","volume":"26","author":"Kim","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2006.01.025_bib14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1396-0296.2003.01648.x","article-title":"Systemic chemotherapy for the treatment of mycosis fungoides and Sezary syndrome","volume":"16","author":"Kuzel","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ejca.2006.01.025_bib15","first-page":"1419","article-title":"Management of mycosis fungoides. Treatment: part 2","volume":"17","author":"Smith","year":"2003","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2006.01.025_bib16","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1365-2133.2003.05698.x","article-title":"Joint British Association of Dermatologists and UK Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas","volume":"149","author":"Whittaker","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib17","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1159\/000072098","article-title":"Therapy of cutaneous lymphoma \u2013 current practice and future developments","volume":"26","author":"Dummer","year":"2003","journal-title":"Onkologie"},{"key":"10.1016\/j.ejca.2006.01.025_bib18","first-page":"514","article-title":"Appraising clinical practice guidelines in England and Wales: the development of a methodologic framework and its application to policy","volume":"25","author":"Cluzeau","year":"1999","journal-title":"Jt Comm J Qual Improv"},{"key":"10.1016\/j.ejca.2006.01.025_bib19","unstructured":"Agency for Healthcare Research and Quality (AHRQ). National Guideline Clearinghouse. Availbale from: http:\/\/www.guideline.gov. Accessed 4 November; 2005."},{"key":"10.1016\/j.ejca.2006.01.025_bib20","unstructured":"Centre for Evidence-Based Medicine. Levels of evidence and grades of recommendation. Availbale from: http:\/\/www.cebm.net\/levels_of_evidence.asp. Accessed 4 November; 2005."},{"key":"10.1016\/j.ejca.2006.01.025_bib21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00000478-200001000-00005","article-title":"Efficacy of histologic criteria for diagnosing early mycosis fungoides: an EORTC cutaneous lymphoma study group investigation. European Organization for Research and Treatment of Cancer","volume":"24","author":"Santucci","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejca.2006.01.025_bib22","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jaad.2005.08.057","article-title":"Defining early mycosis fungoides","volume":"53","author":"Pimpinelli","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib23","first-page":"725","article-title":"Report of the committee on staging and classification of cutaneous T-cell lymphomas","volume":"63","author":"Bunn","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.ejca.2006.01.025_bib24","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2002-05-1597","article-title":"Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma","volume":"101","author":"Toro","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.01.025_bib25","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0190-9622(95)90067-5","article-title":"CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides","volume":"32","author":"Hoppe","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib26","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood.V92.4.1150","article-title":"Transformation of mycosis fungoides\/S\u00e9zary syndrome: clinical characteristics and prognosis","volume":"92","author":"Diamandidou","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.01.025_bib27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1523-1747.2000.00830.x","article-title":"Detection of a peripheral blood T cell clone is an independent prognostic marker in mycosis fungoides","volume":"114","author":"Fraser-Andrews","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib28","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/archderm.136.4.504","article-title":"Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients","volume":"136","author":"van Doorn","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1749-6632.2001.tb03719.x","article-title":"Clinical trials and efficacy assessment in the therapy of cutaneous T cell lymphoma","volume":"941","author":"Heald","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ejca.2006.01.025_bib30","series-title":"Evidence-based dermatology","first-page":"346","article-title":"Primary cutaneous T-cell lymphoma","author":"Whittaker","year":"2003"},{"key":"10.1016\/j.ejca.2006.01.025_bib31","first-page":"1284","article-title":"Topical nitrogen mustard in cutaneous lymphosarcoma (mycosis fungoides)","volume":"87","author":"Watson","year":"1962","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.ejca.2006.01.025_bib32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archderm.139.2.165","article-title":"Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib33","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.1987.5.11.1796","article-title":"Mycosis fungoides: management with topical nitrogen mustard","volume":"5","author":"Hoppe","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.01.025_bib34","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0190-9622(88)70223-6","article-title":"Topical mechlorethamine therapy for early stage mycosis fungoides","volume":"19","author":"Ramsay","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib35","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/archderm.1984.01650480047016","article-title":"Response of mycosis fungoides to topical chemotherapy with mechlorethamine","volume":"120","author":"Ramsay","year":"1984","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib36","first-page":"133","article-title":"Hypopigmented mycosis fungoides: a report of 7 cases and review of the literature","volume":"67","author":"Stone","year":"2001","journal-title":"Cutis"},{"key":"10.1016\/j.ejca.2006.01.025_bib37","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archderm.138.3.325","article-title":"Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma","volume":"138","author":"Breneman","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib38","series-title":"Monograph 1773. Mosby\u2019s GenRx 2000","author":"Methoxsalen","year":"2000"},{"key":"10.1016\/j.ejca.2006.01.025_bib39","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2340\/0001555574465466","article-title":"Indications of a considerable decrease in the death rate in mycosis fungoides by PUVA treatment","volume":"74","author":"Swanbeck","year":"1994","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ejca.2006.01.025_bib40","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/archderm.1987.01660310065016","article-title":"PUVA treatment of erythrodermic and plaque-type mycosis fungoides. Ten-year follow-up study","volume":"123","author":"Abel","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1067\/mjd.2003.80","article-title":"Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study","volume":"48","author":"Diederen","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib42","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S0889-8588(03)00108-4","article-title":"Total skin electron beam radiotherapy for patients who have mycosis fungoides","volume":"17","author":"Jones","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ejca.2006.01.025_bib43","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1067\/mjd.2002.123482","article-title":"Total skin electron radiation in the management of mycosis fungoides: consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group","volume":"47","author":"Jones","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0190-9622(96)90499-5","article-title":"Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma","volume":"35","author":"Wilson","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib45","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/0360-3016(94)00590-H","article-title":"Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides","volume":"32","author":"Becker","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2006.01.025_bib46","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/0360-3016(83)90321-8","article-title":"Palliative radiation treatment of cutaneous mycosis fungoides \u2013 a dose response","volume":"9","author":"Cotter","year":"1983","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2006.01.025_bib47","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2006.01.025_bib48","series-title":"Monograph 3276. Mosby\u2019s GenRx 2000","author":"Liposomal doxorubicin","year":"2000"},{"key":"10.1016\/j.ejca.2006.01.025_bib49","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1200\/JCO.1999.17.10.3117","article-title":"Pentostatin therapy of T-cell lymphomas with cutaneous manifestations","volume":"17","author":"Kurzrock","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.01.025_bib50","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/archderm.135.10.1279","article-title":"Low-dose 2-chlorodeoxyadenosine for the treatment of mycosis fungoides","volume":"135","author":"Trautinger","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib51","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V87.3.906.bloodjournal873906","article-title":"Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma","volume":"87","author":"Kuzel","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.01.025_bib52","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1046\/j.1365-2133.2001.04191.x","article-title":"A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma","volume":"144","author":"Scarisbrick","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib53","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7326\/0003-4819-101-4-484","article-title":"Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas","volume":"101","author":"Bunn","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejca.2006.01.025_bib54","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/blood.V91.2.570","article-title":"Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression","volume":"91","author":"Sun","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.01.025_bib55","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(89)70049-9","article-title":"Interferon alfa-2a in the treatment of cutaneous T cell lymphoma","volume":"20","author":"Olsen","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib56","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/1097-0142(19860415)57:8+<1689::AID-CNCR2820571311>3.0.CO;2-M","article-title":"The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas","volume":"57","author":"Bunn","year":"1986","journal-title":"Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2006.01.025_bib57","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2141.1991.tb08119.x","article-title":"Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice?","volume":"79","author":"Papa","year":"1991","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2006.01.025_bib58","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1200\/JCO.1994.12.6.1185","article-title":"Use of retinoic acids in the treatment of peripheral T-cell lymphoma: a pilot study","volume":"12","author":"Cheng","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.01.025_bib59","series-title":"Monograph. Mosby\u2019s GenRx 2000","author":"Isotretinoin oral","year":"2000"},{"key":"10.1016\/j.ejca.2006.01.025_bib60","series-title":"Monograph 3200. Mosby\u2019s GenRx 2000","author":"Acitretin","year":"2000"},{"key":"10.1016\/j.ejca.2006.01.025_bib61","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2133.1991.tb14772.x","article-title":"The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate","volume":"125","author":"Dreno","year":"1991","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib62","first-page":"29","article-title":"The retinoid X receptor and its ligands: versatile regulators of metabolic function, cell differentiation and cell death","volume":"17","author":"Ahuja","year":"2003","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.ejca.2006.01.025_bib63","series-title":"Monograph 3464. Mosby\u2019s GenRx 2000","author":"Bexarotene","year":"2000"},{"key":"10.1016\/j.ejca.2006.01.025_bib64","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1021\/jm00044a014","article-title":"Synthesis and structure\u2013activity relationships of novel retinoid X receptor-selective retinoids","volume":"37","author":"Boehm","year":"1994","journal-title":"J Med Chem"},{"key":"10.1016\/j.ejca.2006.01.025_bib65","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib66","unstructured":"Committee for proprietary medicinal products. European public assessment report (EPAR): Targretin. European Agency for the Evaluation of Medicinal Products, London; 2001."},{"key":"10.1016\/j.ejca.2006.01.025_bib67","first-page":"1234","article-title":"Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action","volume":"8","author":"Zhang","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2006.01.025_bib68","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1067\/mjd.2002.124607","article-title":"Optimizing bexarotene therapy for cutaneous T-cell lymphoma","volume":"47","author":"Talpur","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib69","series-title":"Monograph 3474. Mosby\u2019s GenRx 2000","author":"Denileukin diftitox","year":"2000"},{"key":"10.1016\/j.ejca.2006.01.025_bib70","first-page":"399","article-title":"Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2","volume":"91","author":"LeMaistre","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.01.025_bib71","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3816\/CLM.2001.n.005","article-title":"Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication","volume":"1","author":"Foss","year":"2001","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.ejca.2006.01.025_bib72","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.01.025_bib73","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V82.3.807.807","article-title":"Effect of Campath-1H antibody on human hematopoietic progenitors in vitro","volume":"82","author":"Gilleece","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.01.025_bib74","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.01.025_bib75","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/blood-2003-07-2345","article-title":"Cardiac toxicity of alemtuzumab in patients with mycosis fungoides\/Sezary syndrome","volume":"104","author":"Lenihan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.01.025_bib76","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM198702053160603","article-title":"Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results","volume":"316","author":"Edelson","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2006.01.025_bib77","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1473-0502(02)00103-9","article-title":"Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma","volume":"28","author":"Knobler","year":"2003","journal-title":"Transfus Apheresis Sci"},{"key":"10.1016\/j.ejca.2006.01.025_bib78","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/archderm.1996.03890350051009","article-title":"Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis","volume":"132","author":"Kim","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib79","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0190-9622(99)70491-3","article-title":"Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients","volume":"40","author":"Zackheim","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib80","first-page":"3578","article-title":"Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II","volume":"92","author":"Stadler","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.01.025_bib81","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0190-9622(84)70030-2","article-title":"Photochemotherapy for cutaneous T cell lymphoma. A follow-up study","volume":"10","author":"Honigsmann","year":"1984","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib82","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2340\/0001555576475478","article-title":"PUVA in early mycosis fungoides may give long-term remission and delay extracutaneous spread","volume":"76","author":"Roupe","year":"1996","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ejca.2006.01.025_bib83","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0190-9622(95)90241-4","article-title":"Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up","volume":"33","author":"Herrmann","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib84","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2340\/00015555614751","article-title":"Photochemotherapy (PUVA) in the pretumour stage of mycosis fungoides: a report from the Scandinavian Mycosis Fungoides Study Group","volume":"61","author":"Molin","year":"1981","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ejca.2006.01.025_bib85","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1001\/archderm.1992.01680170063007","article-title":"Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma","volume":"128","author":"Ramsay","year":"1992","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib86","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/archderm.136.6.748","article-title":"Narrowband TL-01 phototherapy for patch-stage mycosis fungoides","volume":"136","author":"Clark","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib87","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1067\/mjd.2002.120911","article-title":"Narrowband UVB phototherapy for early-stage mycosis fungoides","volume":"47","author":"Gathers","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib88","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archderm.134.8.949","article-title":"Topical corticosteroids for mycosis fungoides. Experience in 79 patients","volume":"134","author":"Zackheim","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib89","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0360-3016(98)00218-1","article-title":"Radiotherapy for unilesional mycosis fungoides","volume":"42","author":"Micaily","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2006.01.025_bib90","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0889-8588(18)30058-3","article-title":"Electron beam treatment for cutaneous T-cell lymphoma","volume":"9","author":"Jones","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ejca.2006.01.025_bib91","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0190-9622(89)70051-7","article-title":"Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma","volume":"20","author":"Vonderheid","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib92","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/0190-9622(90)70112-U","article-title":"Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients","volume":"22","author":"Zackheim","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib93","first-page":"202","article-title":"Topical carmustine (BCNU) for patch\/plaque mycosis fungoides","volume":"13","author":"Zackheim","year":"1994","journal-title":"Semin Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib94","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1396-0296.2003.01641.x","article-title":"Topical carmustine (BCNU) in the treatment of mycosis fungoides","volume":"16","author":"Zackheim","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ejca.2006.01.025_bib95","series-title":"Monograph 0665. Mosby\u2019s GenRx 2000","author":"Carmustine","year":"2000"},{"key":"10.1016\/j.ejca.2006.01.025_bib96","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electronbeam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2006.01.025_bib97","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0889-8588(18)30061-3","article-title":"Chemotherapy for mycosis fungoides and the Sezary syndrome","volume":"9","author":"Rosen","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ejca.2006.01.025_bib98","doi-asserted-by":"crossref","first-page":"206S","DOI":"10.1111\/1523-1747.ep12875616","article-title":"Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma","volume":"95","author":"Zachariae","year":"1990","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib99","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.1990.tb00903.x","article-title":"Interferon alpha-2a in cutaneous T-cell lymphoma","volume":"52","author":"Vegna","year":"1990","journal-title":"Eur J Haematol Suppl"},{"key":"10.1016\/j.ejca.2006.01.025_bib100","first-page":"35","article-title":"Alpha-interferon treatment of cutaneous T cell lymphoma and chronic lymphocytic leukemia","volume":"13","author":"Foon","year":"1986","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2006.01.025_bib101","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jnci\/82.3.208","article-title":"Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma","volume":"82","author":"Kaplan","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2006.01.025_bib102","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1600-0609.1993.tb01595.x","article-title":"Interferon treatment of cutaneous T-cell lymphoma","volume":"51","author":"Ross","year":"1993","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ejca.2006.01.025_bib103","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-121-8-199410150-00007","article-title":"Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome)","volume":"121","author":"Bunn","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejca.2006.01.025_bib104","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0190-9622(91)70036-2","article-title":"Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids","volume":"24","author":"Knobler","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib105","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2133.1999.02704.x","article-title":"Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa","volume":"140","author":"Jumbou","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib106","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0190-9622(03)01591-3","article-title":"Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients","volume":"49","author":"Zackheim","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib107","first-page":"1009","article-title":"Treatment of mycosis fungoides lymphoma: effectiveness of infusions of methotrexate followed by oral citrovorum factor","volume":"62","author":"McDonald","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.ejca.2006.01.025_bib108","series-title":"Monograph 1770. Mosby\u2019s GenRx 2000","author":"Methotrexate","year":"2000"},{"key":"10.1016\/j.ejca.2006.01.025_bib109","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/archderm.1993.01680270085011","article-title":"Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA","volume":"129","author":"Mostow","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib110","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1995.13.1.257","article-title":"Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome","volume":"13","author":"Kuzel","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.01.025_bib111","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/978-3-642-78771-3_30","article-title":"Combination therapy of cutaneous T cell lymphoma with interferon alpha-2a and photochemotherapy","volume":"139","author":"Stadler","year":"1995","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.ejca.2006.01.025_bib112","first-page":"809","article-title":"Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T Cell Lymphoma Multicenter Study Group","volume":"84","author":"Rupoli","year":"1999","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2006.01.025_bib113","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/cncr.10706","article-title":"Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma","volume":"95","author":"Chiarion-Sileni","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2006.01.025_bib114","first-page":"536","article-title":"Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group","volume":"69","author":"Thomsen","year":"1989","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ejca.2006.01.025_bib115","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaad.2003.05.010","article-title":"Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series","volume":"51","author":"Singh","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib116","unstructured":"EORTC (Sponsor): Ultraviolet light therapy using methoxsalen with or without bexarotene in treating patients with Mycosis Fungoides. Availbale from: http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00056056?order=2. Accessed 4 November; 2005."},{"key":"10.1016\/j.ejca.2006.01.025_bib117","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/0360-3016(91)90028-3","article-title":"Total skin electron beam and total nodal irradiation of cutaneous T-cell lymphoma","volume":"20","author":"Micaily","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2006.01.025_bib118","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000249861","article-title":"Retinoid-orale Photochemotherapie (RePUVA) als Kombinationsbehandlung bei Mycosis fungoides","volume":"166","author":"Hunziker","year":"1983","journal-title":"Dermatologica"},{"key":"10.1016\/j.ejca.2006.01.025_bib119","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000418097","article-title":"Combination of retinoids and PUVA (Re-PUVA) in the treatment of cutaneous T cell lymphomas","volume":"19","author":"Serri","year":"1990","journal-title":"Curr Probl Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib120","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II\u2013III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.01.025_bib121","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.01.025_bib122","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.11593","article-title":"Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma","volume":"98","author":"Wollina","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2006.01.025_bib123","doi-asserted-by":"crossref","first-page":"198S","DOI":"10.1111\/1523-1747.ep12875523","article-title":"Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma","volume":"95","author":"Roenigk","year":"1990","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib124","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0190-9622(96)80062-4","article-title":"Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients","volume":"34","author":"Zackheim","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib125","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0190-9622(92)70142-3","article-title":"Combined treatment with oral etretinate and electron beam therapy in patients with cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","volume":"26","author":"Jones","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib126","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/archderm.138.8.1054","article-title":"Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution","volume":"138","author":"Suchin","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib127","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0190-9622(96)90119-X","article-title":"Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution","volume":"35","author":"Gottlieb","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib128","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0190-9622(96)90118-8","article-title":"Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy","volume":"35","author":"Zic","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib129","first-page":"623","article-title":"Treatment of mycosis fungoides with topical BCNU","volume":"63","author":"Zackheim","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.ejca.2006.01.025_bib130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/hon.2900040110","article-title":"Staging and treatment with cyclophosphamide, vincristine and prednisone (CVP) in advanced cutaneous T-cell lymphomas","volume":"4","author":"Tirelli","year":"1986","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ejca.2006.01.025_bib131","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000246116","article-title":"Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma","volume":"194","author":"Fierro","year":"1997","journal-title":"Dermatology"},{"key":"10.1016\/j.ejca.2006.01.025_bib132","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1034\/j.1600-0609.2003.00143.x","article-title":"Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab","volume":"71","author":"Kennedy","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ejca.2006.01.025_bib133","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s004320000178","article-title":"Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up","volume":"127","author":"Wollina","year":"2001","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2006.01.025_bib134","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood.V98.5.1298","article-title":"Extracorporeal photopheresis in Sezary syndrome: hematologic parameters as predictors of response","volume":"98","author":"Evans","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2006.01.025_bib135","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0190-9622(92)70212-X","article-title":"Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy","volume":"27","author":"Heald","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib136","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0190-9622(84)80323-0","article-title":"The treatment of Sezary syndrome","volume":"10","author":"Winkelmann","year":"1984","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2006.01.025_bib137","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1368::AID-CNCR37>3.0.CO;2-8","article-title":"Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma","volume":"86","author":"Akpek","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2006.01.025_bib138","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0190-9622(89)70251-6","article-title":"Low-dose methotrexate for the Sezary syndrome","volume":"21","author":"Zackheim","year":"1989","journal-title":"J Am Acad Dermatol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804906001298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804906001298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T14:55:59Z","timestamp":1706972159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804906001298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":138,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0959804906001298"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2006.01.025","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}